trial · primary record
Infusion of 4SCAR-T specific to CD22/CD123/CD38/ CD10/CD20
CD19 Negative B-cell Malignancies
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2026-07-31 |
| Primary endpoint | Safety of fourth generation anti-CD22/CD123/CD38/CD10/CD20 CAR-T cells |
| Registry ID | NCT04430530 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:42:53.981Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04430530
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.